Related Experiment Video
Updated: Jul 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure
Monica Colvin-Adams1, Anne L Taylor
1Cardiac Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Abstract:
The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057). This placebo-controlled trial was the first to evaluate a therapy in a specific racial group, and it points the way to a more individualized approach to heart failure therapy.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inotropic Agents